EGFR and non-small cell lung carcinoma: Pembrolizumab also significantly improved progression-free survival and OS compared with platinum-based chemotherapy in patients with chemo-naïve advanced NSCLC who had a PD-L1 TPS of 50% or greater and did not have EGFR mutation or anaplastic lymphoma kinase (ALK) rearrangement3,5.